FLT3 and acute myeloid leukemia: As yet another example, encouraging response rates (46% overall response rate [ORR]) were achieved in a nonrandomized study of azacytidine plus sorafenib in patients with relapsed/refractory AML, including 93% with FLT3-ITD mutations [67].